Tags

Type your tag names separated by a space and hit enter

Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease.

Abstract

F2-isoprostanes (F2-IsoPs) are well-established sensitive and specific markers of oxidative stress in vivo. Isofurans (IsoFs) are also products of lipid peroxidation, but in contrast to F2-IsoPs, their formation is favored when oxygen tension is increased in vitro or in vivo. Mitochondrial dysfunction in Parkinson's disease (PD) may not only lead to oxidative damage to brain tissue but also potentially result in increased intracellular oxygen tension, thereby influencing relative concentrations of F2-IsoPs and IsoFs. In this study, we attempted to compare the levels of F2-IsoPs and IsoFs esterified in phospholipids in the substantia nigra (SN) from patients with PD to those of age-matched controls as well as patients with other neurodegenerative diseases, including dementia with Lewy body disease (DLB), multiple system atrophy (MSA), and Alzheimer's disease (AD). The results demonstrated that IsoFs but not F2-IsoPs in the SN of patients with PD and DLB were significantly higher than those of controls. Levels of IsoFs and F2-IsoPs in the SN of patients with MSA and AD were indistinguishable from those of age-matched controls. This preferential increase in IsoFs in the SN of patients with PD or DLB not only indicates a unique mode of oxidant injury in these two diseases but also suggests different underlying mechanisms of dopaminergic neurodegeneration in PD and DLB from those of MSA.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

    , , ,

    Source

    Journal of neurochemistry 85:3 2003 May pg 645-50

    MeSH

    Aged
    Aged, 80 and over
    Alzheimer Disease
    F2-Isoprostanes
    Female
    Furans
    Humans
    Isomerism
    Lewy Body Disease
    Male
    Multiple System Atrophy
    Oxidative Stress
    Parkinson Disease
    Phospholipids
    Substantia Nigra

    Pub Type(s)

    Comparative Study
    Journal Article
    Research Support, Non-U.S. Gov't
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    12694390

    Citation

    Fessel, Joshua P., et al. "Isofurans, but Not F2-isoprostanes, Are Increased in the Substantia Nigra of Patients With Parkinson's Disease and With Dementia With Lewy Body Disease." Journal of Neurochemistry, vol. 85, no. 3, 2003, pp. 645-50.
    Fessel JP, Hulette C, Powell S, et al. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem. 2003;85(3):645-50.
    Fessel, J. P., Hulette, C., Powell, S., Roberts, L. J., & Zhang, J. (2003). Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. Journal of Neurochemistry, 85(3), pp. 645-50.
    Fessel JP, et al. Isofurans, but Not F2-isoprostanes, Are Increased in the Substantia Nigra of Patients With Parkinson's Disease and With Dementia With Lewy Body Disease. J Neurochem. 2003;85(3):645-50. PubMed PMID: 12694390.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. AU - Fessel,Joshua P, AU - Hulette,Christine, AU - Powell,Suzanne, AU - Roberts,L Jackson,2nd AU - Zhang,Jing, PY - 2003/4/16/pubmed PY - 2003/6/18/medline PY - 2003/4/16/entrez SP - 645 EP - 50 JF - Journal of neurochemistry JO - J. Neurochem. VL - 85 IS - 3 N2 - F2-isoprostanes (F2-IsoPs) are well-established sensitive and specific markers of oxidative stress in vivo. Isofurans (IsoFs) are also products of lipid peroxidation, but in contrast to F2-IsoPs, their formation is favored when oxygen tension is increased in vitro or in vivo. Mitochondrial dysfunction in Parkinson's disease (PD) may not only lead to oxidative damage to brain tissue but also potentially result in increased intracellular oxygen tension, thereby influencing relative concentrations of F2-IsoPs and IsoFs. In this study, we attempted to compare the levels of F2-IsoPs and IsoFs esterified in phospholipids in the substantia nigra (SN) from patients with PD to those of age-matched controls as well as patients with other neurodegenerative diseases, including dementia with Lewy body disease (DLB), multiple system atrophy (MSA), and Alzheimer's disease (AD). The results demonstrated that IsoFs but not F2-IsoPs in the SN of patients with PD and DLB were significantly higher than those of controls. Levels of IsoFs and F2-IsoPs in the SN of patients with MSA and AD were indistinguishable from those of age-matched controls. This preferential increase in IsoFs in the SN of patients with PD or DLB not only indicates a unique mode of oxidant injury in these two diseases but also suggests different underlying mechanisms of dopaminergic neurodegeneration in PD and DLB from those of MSA. SN - 0022-3042 UR - https://www.unboundmedicine.com/medline/citation/12694390/Isofurans_but_not_F2_isoprostanes_are_increased_in_the_substantia_nigra_of_patients_with_Parkinson's_disease_and_with_dementia_with_Lewy_body_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0022-3042&date=2003&volume=85&issue=3&spage=645 DB - PRIME DP - Unbound Medicine ER -